Latest Revenue Guidance News

Helia Group reports a robust 38% rise in statutory net profit for the first half of 2025, alongside a special dividend declaration, while navigating looming challenges from government policy shifts and lender contract changes.

Cogstate Limited has reported a landmark FY25 with revenue up 22% and net profit before tax nearly doubling, driven by a surge in clinical trials contracts and strategic innovation. The company also declared its maiden fully franked dividend and outlined ambitious growth plans including AI product launches and an expanding Medidata partnership.

NRW Holdings delivered a robust FY25 performance, posting a 12.2% revenue increase to $3.27 billion and securing a strong $6.1 billion order book. The company’s FY26 outlook remains positive with expected revenue growth and improved earnings.

Megaport Limited delivered a robust FY25 with 20% growth in annual recurring revenue and EBITDA surpassing guidance, setting the stage for continued expansion in FY26.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase in H1 2025, driven by strong sales of its precision medicine products and strategic acquisitions. The company is advancing multiple late-stage clinical trials and expanding its global manufacturing footprint.

Telix Pharmaceuticals reported a robust 63% revenue increase in H1 2025, driven by commercial growth and strategic investments, while advancing key clinical trials and maintaining full-year guidance.

Fisher & Paykel Healthcare has issued strong first half FY26 guidance, forecasting significant revenue and profit growth while navigating new US tariffs. Meanwhile, director Pip Greenwood announces her retirement after eight years on the board.

Vista Group International reports robust H1 2025 results with strong revenue growth and margin expansion, driven by accelerating client adoption of its Vista Cloud platform and a new Embedded Payments initiative.

Austin Engineering has restated its FY24 financials due to revenue recognition errors in its Chilean subsidiary, leading to an upward revision of its FY25 revenue and profit guidance.

Chrysos Corporation reports robust FY25 financial growth driven by global adoption of its PhotonAssay technology and secures a strategic Master Services Agreement with gold giant Newmont. The company projects further revenue and EBITDA expansion in FY26.

AVITA Medical’s Q2 2025 update reveals a temporary setback in RECELL demand due to Medicare reimbursement delays, offset by strong revenue growth and promising clinical data. The company anticipates recovery and renewed growth in the second half of the year.

AVITA Medical reported a 21% increase in Q2 commercial revenue to $18.4 million and narrowed its net loss, yet faces a reimbursement hurdle that forced a downward revision of full-year guidance. The company highlights clinical progress and strategic board appointments as it navigates payment challenges.